Case report and review of the literature: Secretory breast cancer in a 13-year-old boy—10 years of follow up Cesar CabelloMarcelo AlvarengaPriscila Silva Marshall Review 15 November 2011 Pages: 813 - 820
Beyond taxanes: the next generation of microtubule-targeting agents Javier CortesMaria Vidal Review Open access 24 November 2011 Pages: 821 - 830
Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype Aoife J. LoweryMalcolm R. KellKarl J. Sweeney Review 07 December 2011 Pages: 831 - 841
Correlation of breast cancer susceptibility loci with patient characteristics, metastasis-free survival, and mRNA expression of the nearest genes Muhammad RiazEls M. J. J. BernsJohn W. M. Martens Preclinical study 12 July 2011 Pages: 843 - 851
Triggering of Toll-like receptor 4 on metastatic breast cancer cells promotes αvβ3-mediated adhesion and invasive migration Sheng-Jun LiaoYuan-Hong ZhouZuo-Hua Feng Preclinical study 01 November 2011 Pages: 853 - 863
Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival Victor J. WeigmanHann-Hsiang ChaoCharles M. Perou Preclinical Study Open access 03 November 2011 Pages: 865 - 880
Differential oxidative status and immune characterization of the early and advanced stages of human breast cancer C. PanisV. J. VictorinoA. L. Cecchini Preclinical Study 03 November 2011 Pages: 881 - 888
Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma Clint E. JohnsonKylie L. GorringeIan G. Campbell Preclinical study 04 November 2011 Pages: 889 - 898
Local treatment of mixed osteolytic/osteoblastic spinal metastases: is photodynamic therapy effective? L. Wise-MilestoneM. K. AkensC. M. Whyne Preclinical Study 06 November 2011 Pages: 899 - 908
Expression of SPRR3 is associated with tumor cell proliferation in less advanced stages of breast cancer Jin Cheon KimJong Han YuDong-Hyung Cho Preclinical Study 11 November 2011 Pages: 909 - 916
Paclitaxel sensitivity of breast cancer cells requires efficient mitotic arrest and disruption of Bcl-xL/Bak interaction M. Luz FloresCarolina CastillaMiguel A. Japón Preclinical study 11 November 2011 Pages: 917 - 928
Topoisomerase 2A gene amplification in breast cancer. Critical evaluation of different FISH probes Zsuzsanna VargaCathy B. MoelansHolger Moch Preclinical study 15 November 2011 Pages: 929 - 935
High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer M. P. H. M. JansenE. A. ReijmE. M. J. J. Berns Preclinical Study Open access 18 November 2011 Pages: 937 - 947
A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences Abeer M. ShaabanGraham R. BallValerie Speirs Preclinical Study 18 November 2011 Pages: 949 - 958
An in vitro investigation of metabolically sensitive biomarkers in breast cancer progression Natalie E. SimpsonVolodymyr P. TryndyakIgor P. Pogribny Preclinical study 20 November 2011 Pages: 959 - 968
Investigation of human JC and BK polyomaviruses in breast carcinomas Mohamed HachanaKhaled AmaraMounir Trimeche Preclinical Study 23 November 2011 Pages: 969 - 977
A CD44−/CD24+ phenotype is a poor prognostic marker in early invasive breast cancer Mohamed A. H. AhmedMohammed A. AleskandaranyIan O. Ellis Preclinical study 27 November 2011 Pages: 979 - 995
Associated expressions of FGFR-2 and FGFR-3: from mouse mammary gland physiology to human breast cancer Juan P. CerlianiSilvia I. VanzulliCaroline A. Lamb Preclinical Study 29 November 2011 Pages: 997 - 1008
Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia Erik S. KnudsenAdam ErtelAgnieszka K. Witkiewicz Preclinical Study 02 December 2011 Pages: 1009 - 1024
GPER mediates the Egr-1 expression induced by 17β-estradiol and 4-hydroxitamoxifen in breast and endometrial cancer cells Adele VivacquaEnrica RomeoMarcello Maggiolini Preclinical study 07 December 2011 Pages: 1025 - 1035
Ethanol promotes mammary tumor growth and angiogenesis: the involvement of chemoattractant factor MCP-1 Siying WangMei XuJia Luo Preclinical Study 09 December 2011 Pages: 1037 - 1048
A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer Robert W. CarlsonAnne O’NeillGeorge W. Sledge Clinical trial 15 March 2012 Pages: 1049 - 1056
A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab Nancy U. LinEric P. WinerTamas Hickish Clinical Trial Open access 15 March 2012 Pages: 1057 - 1065
Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial Adam BrufskyVicente ValeroDenise A. Yardley Clinical trial 14 March 2012 Pages: 1067 - 1075
25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1 Eitan AmirReena S. CecchiniPamela J. Goodwin Clinical trial Open access 14 March 2012 Pages: 1077 - 1088
Recommendations for antiresorptive therapy in postmenopausal patients with breast cancer: Marburg AIBL Guideline Evaluation Study (MAGES) Peyman HadjiMelanie HartenfelsMatthias Kalder Clinical trial 28 March 2012 Pages: 1089 - 1096
Family history and risk of breast cancer: nurses’ health study Graham A. ColditzKimberly A. KaphingstBernard Rosner Epidemiology 19 February 2012 Pages: 1097 - 1104
Association of CD27 and CD70 gene polymorphisms with risk of sporadic breast cancer in Chinese women in Heilongjiang Province Fengyan XuDalin LiDianjun Li Epidemiology 08 March 2012 Pages: 1105 - 1113
Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer Nathan W. D. LamondChris SkedgelTallal Younis Epidemiology 24 February 2012 Pages: 1115 - 1123
Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort Serena MasciariDeborah A. DillonJudy E. Garber Epidemiology 04 March 2012 Pages: 1125 - 1130
Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass Henry M. KuererSara A. LariKelly K. Hunt Epidemiology 04 March 2012 Pages: 1131 - 1141
Prevalence of BRCA1 and BRCA2 mutations in non-familial breast cancer patients with high risks in Korea: The Korean Hereditary Breast Cancer (KOHBRA) Study Byung Ho SonSei Hyun Ahnthe KOHBRA Research Group and the Korean Breast Cancer Society Epidemiology Open access 02 March 2012 Pages: 1143 - 1152
Recurrent germline mutations in BRCA1 and BRCA2 genes in high risk families in Israel Yael LaitmanMonica SimeonovEitan Friedman Epidemiology 08 March 2012 Pages: 1153 - 1157
Vitamin D threshold to prevent aromatase inhibitor-related bone loss: the B-ABLE prospective cohort study Daniel Prieto-AlhambraSonia ServitjaXavier Nogues Epidemiology 21 March 2012 Pages: 1159 - 1167
Benign thyroid disease is associated with breast cancer: a meta-analysis Prue J. HardefeldtGuy D. EslickSenarath Edirimanne Epidemiology 21 March 2012 Pages: 1169 - 1177
Rare germline large rearrangements in the BRCA1/2 genes and eight candidate genes in 472 patients with breast cancer predisposition E. RouleauB. JessonR. Lidereau Brief Report 05 April 2012 Pages: 1179 - 1190
Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients Roberta FerraldeschiMonica ArnedosMitch Dowsett Brief Report 15 March 2012 Pages: 1191 - 1198
The biological correlates of macroscopic breast tumour structure measured using fractal analysis in patients undergoing neoadjuvant chemotherapy P. Di GiovanniT. S. AhearnR. T. Staff Brief Report 24 March 2012 Pages: 1199 - 1206